



## General

#### Guideline Title

Mild traumatic brain injury.

## Bibliographic Source(s)

Vos PE, Alekseenko Y, Battistin L, Ehler E, Gerstenbrand F, Muresanu DF, Potapov A, Stepan CA, Traubner P, Vecsei L, von Wild K, European Federation of Neurological Societies. Mild traumatic brain injury. Eur J Neurol. 2012 Feb;19(2):191-8. [34 references] PubMed

#### **Guideline Status**

This is the current release of the guideline.

# Recommendations

# Major Recommendations

The levels of evidence (class I-IV) supporting the recommendations and ratings of recommendations (A-C, GPP) are defined at the end of the "Major Recommendations" field.

Clinical Decision Rules for Computed Tomography (CT)

#### Adults

Protocols for initial management in mild traumatic brain injury (MTBI) should include a decision scheme or prediction rule algorithm for the
use of CT after MTBI (Grade A).

#### Children

- In young patients with MTBI and a normal consciousness, prediction rules originally developed for adults may apply when they are 5 years of age or older (Grade C).
- In patients under 5 years of age, prediction rules for the need of CT to detect intracranial haematoma also apply but with a different set of risk factors, such as those applied in the Chalice study or the North American prospective cohort study (Grade A).
- In young patients under 5 years of age, CT is a gold standard for the detection of life-threatening (and other intracranial) abnormalities after MTBI (Grade B).
- In children under 2 years of age, a CT is not indicated if normal mental status, no scalp haematoma except frontal, no loss of consciousness (LOC) or LOC for <5 seconds, non-severe injury mechanism, no palpable skull fracture, and acting normally according to the parents (Grade A).
- In children aged 2 years and older, a CT is not indicated if all apply: a normal mental status, no LOC, no vomiting, non-severe injury mechanism, no signs of basilar skull fracture, and no severe headache (Grade A).

#### Initial Patient Management

• Following acute traumatic brain injury (TBI) all patients should undergo urgent neurological examination, in addition to a surgical examination (preferably according to Advanced Trauma Life Support [ATLS] or Advanced Pediatric Life Support [APLS] guidelines). Furthermore, accurate history taking (including medication), preferably with information being obtained from a witness of the accident or personnel involved in first-aid procedures outside the hospital, is important to ascertain the circumstances (mechanism of injury) under which the accident took place and to assess the duration of LOC and amnesia (GPP).

#### Home Discharge

- Patients with MTBI and a normal neurological examination (including a Glasgow Coma Scale [GCS] = 15), no risk factors (in particular a normal coagulation status, no drug or alcohol intoxication, no other injuries, no suspected non-accidental injury, no cerebrospinal fluid leak) and a normal CT could be observed at home and the patient is admitted only if some extracerebral cause occurred. (Grade A).
- For children under 6 years of age who are discharged home from the emergency department (ED), head injury warning instructions are recommended because of the likelihood of delayed cerebral swelling (GPP).
- Patients with a new and clinically significant traumatic lesion on CT, GCS <15, focal neurological deficit, restlessness or agitation, intoxication with alcohol or drugs, or other extracranial injuries should be admitted to the hospital (Grade C).
- A repeat CT should be considered if the admission CT findings were abnormal or if risk factors are present (Grade C).

#### Clinical Observation

- A complete neurological examination is mandatory after admission and should include assessment of the GCS, pupillary size and reaction to light, and short-term memory. Repeat neurological examination should be carried out, its frequency being dependent on the clinical condition of the patient; if the GCS is <15 it should be every 30 min. Patients with a GCS of 15 should be examined every 30 min, for 2 h, and if no complications or deterioration occurs, every hour for 4 h, thereafter once every 2 h. The use of a neurological checklist may be helpful to document the neurological condition and its course. If deterioration occurs, possible intracranial causes should be evaluated with (repeated) CT (Grade C).
- In-hospital observation of patients with a head injury should only be conducted by professionals competent in the assessment of head injury (GPP).

#### Follow-up

• It is recommended that all patients with MTBI who have been admitted to hospital should be seen at least once in the outpatient clinic in the first 2 weeks after discharge (Grade C). Patients who are discharged immediately should contact their general practitioners, who can decide to refer the patient to the neurologist if complaints persist (Grade C).

#### <u>Definitions</u>:

Evidence Classification Scheme for a Diagnostic Measure

Class I: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.

Class II: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.

Class III: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.

Class IV: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).

Rating of Recommendations for a Diagnostic Measure

Level A rating (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.

Level B rating (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.

Level C rating (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.

Good Practice Point (GPP) Where there was a lack of evidence but consensus was clear the Task Force has stated its opinion as Good Practice Points.

# Clinical Algorithm(s)

The original guideline document contains a decision scheme for initial management in mild traumatic brain injury (modified from the Dutch and Scandinavian guidelines).

# Scope

# Disease/Condition(s)

Mild traumatic brain injury

# Guideline Category

Diagnosis

Evaluation

Management

Risk Assessment

# Clinical Specialty

Emergency Medicine

Family Practice

Internal Medicine

Neurological Surgery

Neurology

Orthopedic Surgery

Pediatrics

Radiology

Surgery

#### **Intended Users**

Hospitals

Physician Assistants

Physicians

Utilization Management

# Guideline Objective(s)

To update guidelines for early management in mild traumatic brain injury with respect to the indication for computed tomography and early management (admission, clinical observation, and follow-up)

## **Target Population**

Adults and children, including infants, who have or who are suspected of having mild traumatic brain injury

#### **Interventions and Practices Considered**

- 1. Establishment of a decision scheme or prediction rule algorithm for the use of computed tomography (CT) in cases of mild traumatic brain injury (MTBI)
- 2. Use of age-appropriate risk assessment
- 3. Initial neurological examination conducted according to Advanced Trauma Life Support (ATLS) and Advanced Pediatric Life Support (APLS) guidelines
- 4. Home discharge based on risk assessment
- 5. Provision of head injury warning instructions to parents of discharged children under 6 years of age
- 6. Hospitalization based on outcome of risk assessment
- 7. Repeat CT as appropriate
- 8. Complete neurological examination after admission
- 9. Frequency of repeat neurological examinations
- 10. Timing of follow-up after discharge

## Major Outcomes Considered

- Sensitivity, specificity, and negative predictive value of computed tomography (CT) for detecting mild traumatic brain injury (MTBI)
- Sensitivity and specificity of clinical decision rules for use of CT
- Rates of CT abnormalities
- Rates of adverse outcomes from MTBI (e.g., mortality, need for neurosurgical intervention, and rates of clinically significant brain injury)

# Methodology

#### Methods Used to Collect/Select the Evidence

Hand-searches of Published Literature (Primary Sources)

Hand-searches of Published Literature (Secondary Sources)

Searches of Electronic Databases

# Description of Methods Used to Collect/Select the Evidence

A systematic search of the English literature in the MEDLINE, EMBASE, Cochrane database (2001–2009) using the key words minor head injury, mild head injury, mild traumatic brain injury, traumatic brain injury, guidelines, and management. Additional articles were identified from the bibliographies of the articles retrieved, and from textbooks. Articles were included if they contained data on classification system used (i.e., admission Glasgow Coma Scale [GCS] 13–15) and outcome data (computed tomography [CT] abnormalities, need for neurosurgical intervention, mortality) or management. Articles judged to be of historical value and existing (new) guidelines were also included and reviewed for useful data.

#### Number of Source Documents

## Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

## Rating Scheme for the Strength of the Evidence

Evidence Classification Scheme for a Diagnostic Measure

Class I: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.

Class II: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.

Class III: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation.

Class IV: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls).

## Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review

# Description of the Methods Used to Analyze the Evidence

Where appropriate, a classification of evidence level was given for interventions and diagnostic tests (see the "Rating Scheme for the Strength of the Evidence" field).

#### Methods Used to Formulate the Recommendations

Expert Consensus

# Description of Methods Used to Formulate the Recommendations

Where appropriate, grades of recommendation were given for management according to the neurological management guidelines of the European Federation of Neurological Societies (EFNS). Where there was a lack of evidence but consensus was clear the Task Force has stated their opinion as Good Practice Points (GPP) (see the "Rating Scheme for the Strength of Recommendations" field).

# Rating Scheme for the Strength of the Recommendations

Rating of Recommendations for a Diagnostic Measure

Level A rating (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.

Level B rating (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.

Level C rating (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.

Good Practice Point (GPP) Where there was a lack of evidence but consensus was clear the Task Force has stated its opinion as Good Practice Points.

## Cost Analysis

A formal cost analysis was not performed and published cost analyses were not reviewed.

#### Method of Guideline Validation

Peer Review

## Description of Method of Guideline Validation

The guidelines were validated according to the European Federation of Neurological Societies (EFNS) criteria (see the "Availability of Companion Documents" field).

# Evidence Supporting the Recommendations

## Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

# Benefits/Harms of Implementing the Guideline Recommendations

#### Potential Benefits

Appropriate diagnosis, evaluation, and management of mild traumatic brain injury

#### Potential Harms

There is a lifetime cancer mortality risk attributable to radiation to children from computed tomography.

# **Qualifying Statements**

# **Qualifying Statements**

This guideline provides the view of an expert task force appointed by the Scientific Committee of the European Federation of Neurological Societies (EFNS). It represents a peer-reviewed statement of minimum desirable standards for the guidance of practice based on the best available evidence. It is not intended to have legally binding implications in individual cases.

# Implementation of the Guideline

## Description of Implementation Strategy

The European Federation of Neurological Societies has a mailing list and all guideline papers go to national societies, national ministries of health, World Health Organisation, European Union, and a number of other destinations. Corporate support is recruited to buy large numbers of reprints of the guideline papers and permission is given to sponsoring companies to distribute the guideline papers from their commercial channels, provided there is no advertising attached.

## Implementation Tools

Clinical Algorithm

Staff Training/Competency Material

For information about availability, see the Availability of Companion Documents and Patient Resources fields below.

# Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need

Getting Better

#### **IOM Domain**

Effectiveness

Safety

Timeliness

# Identifying Information and Availability

# Bibliographic Source(s)

Vos PE, Alekseenko Y, Battistin L, Ehler E, Gerstenbrand F, Muresanu DF, Potapov A, Stepan CA, Traubner P, Vecsei L, von Wild K, European Federation of Neurological Societies. Mild traumatic brain injury. Eur J Neurol. 2012 Feb;19(2):191-8. [34 references] PubMed

# Adaptation

Not applicable: The guideline was not adapted from another source.

#### Date Released

2012 Feb

# Guideline Developer(s)

European Academy of Neurology - Medical Specialty Society

# Source(s) of Funding

European Federation of Neurological Societies

#### Guideline Committee

European Federation of Neurological Societies Task Force on Mild Traumatic Brain Injury

## Composition of Group That Authored the Guideline

Task Force Members: P. E. Vos, Radboud University Nijmegen Medical Centre, The Netherlands; Y. Alekseenko, Vitebsk Medical University, Vitebsk, Belarus; L. Battistin, IRCCS San Camillo Hospital, Venice, Italy; E. Ehler, Neurologicka Klinika, Pradubice, Czech Republic; F. Gerstenbrand, Ludwig Boltzmann Institute for Restorative Neurology and Neuromodulation, Vienna, Austria; D. F. Muresanu, University CFR Hospital, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; A. Potapov, Institute of Neurosurgery, Russian Academy of Medical Sciences, Moscow, Russia; C. A. Stepan, Neurological Hospital Rosenhügel, Vienna, Austria; P. Traubner, Comenius University School of Medicine, Bratislava, Slovak Republic; L. Vecsei, Szent-Györgyi University Hospital, Szeged, Hungary; and K. von Wild, Medical Faculty Westphalien University Münster and International Neuroscience Institute INI, Hannover, Germany

#### Financial Disclosures/Conflicts of Interest

The authors have reported no conflict of interest relevant to this manuscript.

#### Guideline Status

This is the current release of the guideline.

# Guideline Availability

from the European Federation of Neurological Societies Web site
---

## Availability of Companion Documents

The following are available:

- Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces revised recommendations 2004. Eur J Neurol. 2004 Sep;11(9):577-81. Electronic copies: Available in Portable Document Format (PDF) from the European Federation of Neurological Societies (EFNS) Web site
- Continuing Medical Education questions are available to registered users from the EFNS Web site

#### **Patient Resources**

None available

#### **NGC Status**

This NGC summary was completed by ECRI Institute on November 20, 2012. The information was verified by the guideline developer on February 12, 2013.

# Copyright Statement

This NGC summary is based on the original guideline, which is subject to the Wiley Online Library copyright restrictions.

# Disclaimer

#### NGC Disclaimer

The National Guideline Clearinghouseâ, & (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.